Summary:

After two days, the ninth edition of India Pharma 2026, which was organized by the Department of Pharmaceuticals alongside FICCI and IPA, came to an end with a focus on bolstering the biopharma ecosystem. Plenary and valedictory sessions on financing ecosystems and innovation-led growth were held on the second day. Twenty partner organizations, ten sessions, more than 60 speakers, and more than 800 delegates. Strategic investments, increased infrastructure, and quicker implementation were identified as important facilitators of change throughout discussions. breakthroughs in biologics, next-generation medications, and sophisticated therapies. Venture capital, private equity, blended finance, and PPPs to fund R&D were among the financing requirements. Collaboration between government, academia, and industry was emphasized by executives from Sun Pharma, Zydus, and Eli Lilly. The event reaffirmed India's goal of becoming a global center for pharmaceutical innovation and AI-enabled transformative growth ecosystems.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.